Skip to main content

Lapse in Appropriations

Please note that a lapse in appropriations has caused GAO to shut down its operations. Therefore, GAO will not be able to publish reports or otherwise update this website until GAO resumes operations. In addition, the vast majority of GAO personnel are not permitted to work. Consequently, calls or emails to agency personnel may not be returned until GAO resumes operations. For details on how the bid protest process will be handled during the shutdown, please see the legal decisions page. For information related to the GAO Personnel Appeals Board (PAB), please see the PAB webpage.

Contract Management: DOD's Anthrax Vaccine Manufacturer Will Continue to Need Financial Assistance

T-NSIAD-00-140 Published: Apr 14, 2000. Publicly Released: Apr 14, 2000.
Jump To:

Highlights

Pursuant to a congressional request, GAO discussed the contractual relationship between the Department of Defense (DOD) and BioPort Corporation for production of the anthrax vaccine, focusing on: (1) the financial assistance DOD provided BioPort in 1999; and (2) additional financial assistance DOD is providing BioPort in 2000.

Full Report

Full Report (7 pages)

Media Inquiries

Sarah Kaczmarek
Managing Director
Office of Public Affairs
media@gao.gov

Public Inquiries

Contact Us

Topics

Homeland Security
Advance paymentsBiological warfareChemical agentsBiological agentsAnthraxContract modificationsContract performanceContract termsDefense procurementDepartment of Defense contractorsFinancial analysisImmunization programsImmunization services